Clinical trials: Human Papillomavirus (HPV) Vaccines
Cervical Cancer, Condylomata Acuminata
An Immuno-bridging Study of a Nonavalent HPV Vaccine (E.Coli) in Healthy Population Aged 9-17 vs Aged 18-26 Years Old
This is a open label clinical trial to evaluate the safety and immunogenicity of a Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58)Vaccine(E.Coli) manufactured by Xiamen Innovax Biotech CO., Ltd., in…
- Trial name
- NCT05056402
- Testing
- 3 doses of the Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58 )Vaccine(E.Coli), 2 doses of theRecombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58 )Vaccine(E.Coli)
- Where
- China
- Volunteers
- 1,382 people, healthy volunteers welcome
- Sponsor
- Xiamen University
Systemic Lupus Erythematosus
Long-term Immunogenicity of a HPV Vaccine in SLE
To study the 5-year immunogenicity against a quadrivalent HPV vaccine in patients with SLE and healthy controls.
- Trial name
- NCT02477254
- Testing
- Vaccination
- Where
- China
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Tuen Mun Hospital
Infections, Papillomavirus
A Single Centre Study to Evaluate the Safety and Immunogenicity of the Human Papillomavirus Vaccine (GSK-580299) in Chinese Females
A phase I, open label, single-centre study to evaluate the safety and immunogenicity of GlaxoSmithKline Biologicals' HPV -16/18 L1 VLP AS04 vaccine (GSK 580299, Cervarix TM), administered intramuscularly according to a 0, 1…
- Trial name
- NCT00549900
- Testing
- GSK580299 (Cervarix™ , HPV -16/18 L1 VLP AS04 vaccine)
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Cervical Cancer, Vulvar Cancer
Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
This study is designed to evaluate the vaccine efficacy, immunogenicity and safety of the 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female…
- Conditions
- Cervical Cancer, Vulvar Cancer, Vaginal Cancer, CIN1
- Trial name
- NCT04422366
- Testing
- 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha), GARDASIL®
- Where
- China
- Volunteers
- 8,000 people, healthy volunteers welcome
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
Cervical Cancer, Genital Warts
Alternate Dosing Schedules Study for HPV Vaccine
To determine if delayed dosing of recombinant human papillomavirus (HPV) quadrivalent (Types 6, 11, 16, and 18) vaccine in 9-18 year old girls elicits an equivalent immune response (geometric mean titers to HPV 6,11,16, and 18 as…
- Trial name
- ADS (NCT00862810)
- Testing
- Received HPV vaccine first, Received concomitant vaccines first
- Where
- 3 sites in United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Duke University
Cervical Cancer Prevention
Study on the Safety, Humoral Immune Response, and Memory B Cell Response Characteristics of Sequential 9-Valent HPV Vaccination
This is a single-center, prospective, open-label, partially randomized, matched-controlled trial designed as a cohort study. The study plans to enroll 360 healthy female participants aged 18 to 45 years, divided into three…
- Trial name
- NCT07530679
- Testing
- 9-valent HPV vaccination at months 0 and 6, 9-valent HPV vaccination at months 0 , 1 and 6
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- Jiangsu Province Centers for Disease Control and Prevention
Papilloma Viral Infection
Immunogenicity of Off-Schedule Dosing of HPV Vaccine
The purpose of this study is to gain a better understanding of the body's response to a human papillomavirus (HPV) (sexually transmitted disease), vaccine and booster shot.
- Trial name
- NCT01030562
- Where
- 7 sites in United States
- Volunteers
- 1,321 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HPV Infections
A Phase 1 Study of PV-001 9-valent Human Papillomavirus(HPV) Vaccine
Study Title: Evaluation of the Safety and Immunogenicity of a Third Dose of PV-001 in Healthy Women Aged 19-45 Objective: To assess the safety and antibody response of a third dose of PV-001 in healthy adult female participants.
- Trial name
- HPV (NCT07081334)
- Testing
- PV-001, PEV-001
- Where
- South Korea
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- POSVAX
Cervical Cancer
Delivery, Uptake and Acceptability of HPV Vaccination in Tanzanian Girls
The aims of this study are: 1. To determine feasibility of a school-based human papillomavirus (HPV) vaccination programme in Tanzania. 2.
- Trial name
- NCT01173900
- Testing
- Gardasil® HPV vaccine
- Where
- Tanzania
- Volunteers
- 5,532 people, healthy volunteers welcome
- Sponsor
- London School of Hygiene and Tropical Medicine
Human Papillomavirus Vaccines
Developing a Self-persuasion Intervention Promoting Adolescent HPV Vaccination
HPV vaccine coverage among adolescents in the US is suboptimal. This is particularly true among traditionally underserved adolescents. Few parent-targeted interventions have focused on the parental decision-making process.
- Trial name
- NCT02537756
- Testing
- Project Voice
- Where
- United States
- Volunteers
- 737 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Cervix, Dysplasia, HPV Infection
Retrospective Cohort Study of the Effectiveness of the Prophylactic Vaccine Against the Human Papilloma Virus in the Prevention of Recurrence in Women Who Have Received an Excisional Therapy by HSIL / CIN.
A retrospective cohort study of women treated by excisional therapy due to HSIL/ CIN at Clínico San Carlos Hospital between 2012-2018.
- Conditions
- Cervix, Dysplasia, HPV Infection, HPV Vaccine, Cervix Lesion
- Trial name
- VENUS (NCT04171505)
- Testing
- HPV vaccine
- Where
- Spain
- Volunteers
- 508 people
- Sponsor
- Hospital San Carlos, Madrid
Incident HPV16, 18, 31, 33, 45, 52 or 58 Infection
Vaccine Effectiveness of One Dose of the Nonavalent Human Papillomavirus (HPV) Vaccine Among Young-adult Women in Sweden Among Women Participating in a Clinical Trial of Concomitant HPV Vaccination and Screening
This study aims to evaluate the vaccine effectiveness of 1 dose the nonavalent human papillomavirus (HPV) vaccine against HPV16, 18, 31, 33, 45, 52, and 58 infection among young adult women in Sweden participating in a nationwide…
- Trial name
- FASTER1DOSE (NCT07314307)
- Testing
- Gardasil 9 2 dose regimen
- Where
- Sweden
- Volunteers
- 150,000 people, healthy volunteers welcome
- Sponsor
- Karolinska Institutet
Paediatric Kidney or Liver Transplantation, Chronic Kidney Disease
Prevention of Human Papillomavirus (HPV) Infection in Paediatric Kidney and Liver Transplant Recipients and in Paediatric Patients With Advanced Chronic Kidney Disease
Due to their immunosuppressive therapy, solid-organ transplant (SOT) recipients bear a 10 to 100 times higher risk of human papillomavirus (HPV)-associated malignancies than healthy individuals.
- Trial name
- NCT03100682
- Where
- Germany
- Volunteers
- 140 people
- Sponsor
- University Hospital Heidelberg
Human Papilloma Virus Infection Type 11, Human Papilloma Virus Infection Type 16
HPV Vaccination: Evaluation of Reminder Prompts for Doses 2 & 3
Randomized, 2-arm observational study. The 2 arms (randomized at the level of health care provider) will be: 1. usual practice; 2.
- Conditions
- Human Papilloma Virus Infection Type 11, Human Papilloma Virus Infection Type 16, Human Papilloma Virus Infection Type 18, Human Papilloma Virus Infection Type 6
- Trial name
- NCT02558803
- Testing
- Simple Reminder
- Where
- 5 sites in United States
- Volunteers
- 1,305 people
- Sponsor
- Regenstrief Institute, Inc.
Infections, Papillomavirus
Safety and Immunogenicity of GlaxoSmithKline Biologicals' HPV Vaccine 580299 (Cervarix) in HIV Infected Females
Infection with human papillomavirus (HPV) has been clearly established as the central cause of cervical cancer. The current study is designed to evaluate the safety and immunogenicity of GlaxoSmithKline Biologicals' HPV vaccine…
- Trial name
- NCT00586339
- Testing
- Cervarix
- Where
- South Africa
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Infections, Papillomavirus
Immunogenicity and Safety of GSK Biologicals' HPV Vaccine 580299 in Healthy Japanese Females 10-15 Years of Age
Human papillomavirus (HPV) infection has been established as a necessary cause of cervical cancer. GSK Biologicals has developed an HPV vaccine (580299) which targets the 2 most common oncogenic HPV types (HPV-16 and HPV-18)…
- Trial name
- NCT00492544
- Testing
- Cervarix™ (HPV-16/18 L1 VLP AS04)
- Where
- 5 sites in Japan
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Genital Infection Viral, HUMAN PAPILLOMA VIRUS
Phase II Study of HPV Therapeutic Vaccine in HPV Infected Women With Normal Cytology or ASCUS/LSIL
Human Papillomavirus (HPV) 16 and HPV 18 (the two virus genotypes targeted by the ProCervix vaccine) are the most common HPV genotypes associated with at least 70% of squamous cell carcinomas and 82% of adenocarcinomas of the…
- Trial name
- RHEIA-VAC (NCT01957878)
- Testing
- ProCervix
- Where
- 40 sites in Belgium, Finland and 5 more
- Volunteers
- 239 people
- Sponsor
- Genticel
Infections, Papillomavirus
Safety Evaluation of the GSK-580299 Vaccine in Women From the Control Group in the Primary NCT00294047 Study
This extension study is designed to assess the safety of GSK Biological's human papillomavirus (HPV) vaccine GSK580299 in female subjects who took part in the primary study NCT00294047 and received the control vaccine in…
- Trial name
- NCT01190189
- Testing
- GSK580299 (Cervarix)
- Where
- 28 sites in United States, Canada
- Volunteers
- 137 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Papillomavirus Infections
Human Papillomavirus (HPV) Registration Study (Gardasil)(V501-023)(COMPLETED)
This is an immunogenicity and safety study of Gardasil (V501) in females 9 to 23 years of age in Korea.
- Trial name
- NCT00157950
- Testing
- Gardasil™
- Volunteers
- 176 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Healthy
AI Chatbot for HPV Vaccine Literacy Among Caregivers in Japan
The goal of this study is to learn if an innovative digital artificial intelligence (AI)-based communication tool works to enhance health literacy among Japanese caregivers regarding Human Papillomavirus (HPV) vaccination.
- Trial name
- NCT06702423
- Testing
- AI-based chatbot, Leaflet
- Where
- United Kingdom
- Volunteers
- 804 people, healthy volunteers welcome
- Sponsor
- The University of Hong Kong